• Ana Amancio Santos Da Silva, Marina Viegas Moura Rezende Ribeiro, Célio Fernando de Sousa-Rodrigues, and Fabiano Timbó Barbosa.
• MSc in Health Sciences, Universidade Federal de Alagoas (Ufal), Maceió, AL, Brazil.
• Rev Assoc Med Bras (1992). 2017 Mar 1; 63 (3): 261-267.

Objective:Determine whether there is an association between the risk of cardiovascular adverse events and the use of antipsychotic agents.Method:Analysis of original articles retrieved from the following databases: LILACS, PubMed, Cochrane Controlled Trials Clinical Data Bank (CENTRAL) and PsycINFO, without language restriction, dated until November 2015. After screening of 2,812 studies, three cohort original articles were selected for quality analysis.Results:403,083 patients with schizophrenia and 119,015 participants in the control group data were analyzed. The occurrence of cardiovascular events observed in the articles was: 63.5% (article 1), 13.1% (article 2) and 24.95% (article 3) in the group of treated schizophrenic patients, and 46.2%, 86.9% and 24.9%, respectively, in the control groups.Conclusion:Clinical heterogeneity among the studies led to a provisional response and made it impossible to perform the meta-analysis, although the articles demonstrate an association between cardiovascular adverse events and the use of antipsychotics. More quality clinical trials are needed to support this evidence.

12 keywords...

hide…